Gurgaon-based biotechnology company Premas Biotech has announced that their new triple-antigen COVID-19 vaccine candidate, PRAK-03202, showed to induce neutralizing immune response against SARS-CoV2 when tested in the mice models.
PRAK -03202 is a yeast-based triple antigen virus-like particle (VLP) vaccine candidate. It is prepared by using three surface antigens from the COVID-19 virus SARS-CoV-2 namely spike, membrane and envelope (S, M and E) proteins.
The four-week-long study was carried out in 50 mice models, separated into 10 cohorts dosed with 5, 10 and 20 micrograms of the PRAK-03202 vaccine candidate. The vaccine candidate was generally well tolerated and safe at all doses, with no adverse events, reported the company.
The vaccine candidate was safe even at higher doses and could generate a robust immune response against all three SARS-Cov2 antigens, S, M and E. PRAK-03202 elicited neutralizing antibody titer levels in all doses, from 5 microgram to 20 microgram dose regimens. The findings showed that after three doses in mice, all groups cohorts revealed binding antibody levels similar to convalescent patients’ levels.
The company is in talks with the regulatory authorities concerned to plan and initiate the next steps towards conducting human trials.
“We have engaged with the regulatory authorities in India and are working towards the next steps under their guidance.” said Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, said in a statement .